Is Imunon Inc (IMNN) overvalued? · rev $500.0K
Imunon Inc (IMNN) is a biotechnology company listed on US.
This page asks whether Imunon Inc (IMNN) looks expensive on cached numbers — not a short thesis.
Latest reported IMNN revenue for 2022-12-31 was $500.0K. Net income was -$35.9M. IMNN currently screens at market cap $9.2M.
IMNN currently screens at market cap $9.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IMNN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IMNN stock page for the full model, not this heading.
Not investment advice.